Human menstrual blood-derived stem cells reverse sorafenib resistance in hepatocellular carcinoma cells through the hyperactivation of mitophagy

Abstract Background Sorafenib is a first-line drug targeting the RTK-MAPK signalling pathway used to treat advanced hepatocellular carcinoma (HCC). However, tumour cells readily develop sorafenib resistance, limiting long-term therapy with this drug. In our previous study, we found that human menstr...

全面介紹

書目詳細資料

Principais autores:	Sining Zhou, Yiming Liu, Qi Zhang, Huikang Xu, Yangxin Fang, Xin Chen, Jiamin Fu, Yin Yuan, Yifei Li, Li Yuan, Charlie Xiang
格式:	Artigo
語言:	Inglês
出版:	BMC 2023-04-01
叢編:	Stem Cell Research & Therapy
主題:	Hepatocellular carcinoma Sorafenib resistance MenSCs Combination therapy
在線閱讀:	https://doi.org/10.1186/s13287-023-03278-8
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!